{
    "symbol": "AUTL",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-07 23:59:04",
    "content": " The net increase in research and development expenses of $6.1 million was primarily due to the following: An increase in clinical costs and manufacturing costs primarily related to the obe-cel clinical product candidate, which is $3.5 million, an increase of $1.4 million in salaries and other employment-related costs, including share-based compensation expense, which is mainly driven by an increase in the number of employees in Asian R&D activities, an increase of $1.4 million in legal and professional consulting fees in relation to the company's R&D activity, an increase of $0.5 million related to information technology infrastructure and support for information systems related to the conduct of clinical trials and manufacturing operations. These increased by $1.1 million to $8.3 million for the three months ended June 30, 2022, compared with $7.2 million for the three months ended June 30, '21, primarily due to the following: an increase of $1.3 million in salaries and other employment-related costs, including share-based compensation expenses and an increase of $0.1 million primarily related to higher directors and officers liability insurance premiums as well as certain professional fees and information technology costs."
}